# Novo Nordisk A/S (NVO) stock news and updates

As of November 16, 2026. Source: https://www.clearthesis.ai/updates/NVO

## Our view on the Novo Nordisk A/S investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/NVO

## Latest updates on Novo Nordisk A/S

### European regulators approved a new hemophilia treatment

*November 16, 2026 · news · significance: notable · signal: positive*

European regulators approved a new Novo Nordisk medicine to treat hemophilia, a rare condition where blood does not clot properly. While the company is most famous for its weight-loss and diabetes drugs, it has a long history in rare disease treatments like this one. This approval adds a new source of revenue to the business. It helps show that the company can still win in specialized medical fields even as it spends most of its energy on the massive global demand for obesity medications.

Sources: [WSJ](https://www.wsj.com/health/pharma/novo-nordisk-shares-rise-on-positive-weight-loss-data-hemophilia-drug-approval-834e79f8)

### Wegovy pill showed 6 percent weight loss in three months

*November 16, 2026 · news · significance: notable · signal: positive*

New data from actual patients shows that the pill version of Wegovy led to about a 6 percent weight loss after three months of use. This matches the results seen in earlier, more controlled clinical trials. Proving the pill works just as well in the real world is vital for the company. Moving patients from a weekly injection to a daily pill is a major part of its plan to keep customers as more competitors launch their own injectable drugs.

Sources: [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/novos-wegovy-pill-helps-patients-lose-about-6-weight-three-months-real-world-2026-11-14/)

### Wegovy helped children under 12 lose weight in a new trial

*November 16, 2026 · news · significance: notable · signal: positive*

Novo Nordisk released data showing that its weight-loss drug, Wegovy, helped children between the ages of 6 and 12 significantly lower their body mass index. While the drug is already used for teenagers, there are currently no approved weight-loss medications for this younger age group. Opening up treatment for younger children would expand the number of people eligible for the drug. For a company trying to stay ahead of rivals, being the first to prove a drug is safe and effective for a new group of patients is a key way to protect its lead in the market.

Sources: [CNBC](https://www.cnbc.com/2026/11/16/novo-wegovy-obesity-children-trial.html)

### Wegovy showed better liver health results than a rival drug in a new study

*November 9, 2026 · news · significance: notable · signal: positive*

New data presented at a major liver conference showed that patients taking Wegovy lost more weight and saw better improvements in liver enzymes than those taking resmetirom, a drug specifically approved for a type of liver disease called MASH. Patients on Wegovy lost about 19 pounds on average over six months. This is important because it shows Wegovy’s benefits likely extend far beyond weight loss and diabetes. If the company can prove the drug effectively treats liver disease, it opens up a massive new group of patients and makes the drug even harder for insurance companies to stop covering.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/novo-real-world-studies-link-wegovy-2-4-mg-to-reductions-in-liver-enzymes-weight-and-blood-sugar-in-adults-with-mash-at-the-liver-meeting-aasld-2026--302932360.html)

### FDA orders new eye risk warnings for Ozempic

*November 9, 2026 · legal · significance: notable · signal: watch*

The FDA informed doctors and patients on Monday that labels for GLP-1 drugs, the class of medicine that includes Ozempic and Wegovy, must now include warnings about a potential risk of a serious eye condition. This condition can cause sudden vision loss. While this adds a new safety concern for doctors to weigh, it is common for labels to be updated as millions more people use these drugs and rare side effects become visible. The main question for the company is whether this warning slows down new prescriptions, but so far, the high demand for these treatments has outweighed similar label updates in the past.

Sources: [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-orders-new-eye-risk-warnings-ozempic-zepbound-2026-11-09/)

## Novo Nordisk A/S earnings

In Q3 2026, reported on November 4, 2026, Novo Nordisk A/S posted earnings of $0.89 per share against $0.73 expected, and revenue of $11.9 billion against $11.1 billion expected.

The next earnings report is expected on February 3, 2027. Analysts expect $0.68 per share. Revenue is expected around $11.8 billion.

What to watch: Whether gross margins can stop falling, as it shows if the company can keep profits high while lowering prices to compete.

## What's ahead for Novo Nordisk A/S

- February 3, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/NVO
